Takeda announces handful of pipeline cuts in effort to pivot resources
Title
Takeda Streamlines Drug Pipeline and Workforce Amid Strategic Resource Pivot
Keywords
- Takeda
- pipeline cuts
- drug development
- resource allocation
- restructuring
- layoffs
- zamaglutenase (TAK-062)
- TAK-186
- dazostinag (TAK-676)
- TAK-280
- R&D
- biopharma
- solid tumors
- celiac disease
Key Facts
- Takeda has announced a series of pipeline cuts as part of a strategic effort to pivot resources and improve operational efficiency2.
- The discontinued programs include:
- Phase 2 trials for zamaglutenase (TAK-062) targeting celiac disease.
- Phase 2 programs for TAK-186 (for EGFR-expressing solid tumors).
- Phase 2 programs for dazostinag (TAK-676) in solid tumors.
- Phase 1 trial for TAK-280 focused on B7-H3 expressing solid tumors.
- This move is part of a wider company restructuring that also includes workforce reductions and organizational simplification in both the U.S. and Europe25.
- Takeda has implemented layoffs at its U.S. headquarters in Massachusetts and has also closed R&D operations at its adeno-associated virus (AAV) gene therapy plant in Orth, Austria5.
- The restructuring aims to enable Takeda to reallocate resources to its late-stage pipeline and other high-priority projects, supporting future growth and operational sustainability12.
- Despite these reductions, Takeda remains committed to advancing select late-stage assets, with three Phase 3 readouts expected in 2025 for promising new treatments4.
Sources:
1. https://www.takeda.com/newsroom/newsreleases/2025/takeda-announces-fy2024-full-year-results-and-fy2025-outlook/
2. https://www.biopharmadive.com/news/takeda-restructuring-layoffs-pipeline-first-quarter-2024/715629/
4. https://endpts.com/takeda-scraps-programs-as-it-raises-full-year-guidance/
5. https://www.fiercepharma.com/pharma/takeda-details-another-round-layoffs-ma-restructuring-drive-rolls